MedTrace Logo

Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China

NCT01863485 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-07-05

No results posted yet for this study

Summary

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors.

Conditions

Interventions

DRUG

CM082 Tablet

CM082 tablets taken orally once a day on 28-day cycles

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER

  • AnewPharma

    lead INDUSTRY

Principal Investigators

  • Jin-Wan Wang, M.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-10-31
Completion
2016-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01863485 on ClinicalTrials.gov